Drug Profile
Research programme: cell surface glycoprotein modulators - Facet Biotech
Alternative Names: PDL241Latest Information Update: 24 Jan 2013
Price :
$50
*
At a glance
- Originator PDL BioPharma
- Class Monoclonal antibodies
- Mechanism of Action Surface antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Immunological disorders
Most Recent Events
- 21 Apr 2010 Facet Biotech Corporation has been acquired by Abbott Laboratories
- 19 Aug 2008 Preclinical trials in Immunological disorders in USA (IV)
- 19 Aug 2008 Preclinical trials in Cancer in USA (IV)